Upstate Active Clinical Trials
Study Title:High Dose Cyclophosphamide, BCNU, Etoposide (CBV) or Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) and Autologous Hematopoietic Stem Cell Transplantation for Resistant and Relapsed Hodgkin's Disease and Non-Hodgkin's Lymphoma.
What is the purpose of the study?To provide autologous transplantation for patients with Hodgkin's Disease.
Upstate Institutional Review Board (IRB) Number:230057
Study/Protocol ID:BMT 9202
Patient Age Group:Adults
Principal Investigator:Dorothy C Pan, MD
Who is eligible?Diagnosis of Hodgkin's disease, acceptable laboratory values, HIV negative, no serious or uncontrolled organ dysfunction.
What is involved if I participate?
- How long is the study?
Inpatient stay approximately 21 days, followed for a lifetime.
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
- What tests and procedures are involved?
Detailed history & physical to determine eligibility, laboratory tests, x-rays/scans, as necessary, bone marrow biopsy & aspirate as necessary, laboratory tests during hospital admission, dental clearance prior to transplant.
Where will the study take place?SUNY Upstate Medical University, Syracuse, NY
Who can I contact for more information?
Name: Shramika Pokharel, MBBS, MPH